Lung Cancer Trials
Select Clinical Trial
Protocol Number: CALGB 30610
Protocol Title: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Eligibility: Men or women, ages 18 and older, diagnosed with limited-stage small-cell lung cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: EA5161
Protocol Title: Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Eligibility: Men or women, ages 18 and older, diagnosed with extensive stage/advanced small cell lung cancer
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: ALCHEMIST
Protocol Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Eligibility: Men or women, ages 18 or older, diagnosed with Stage IIIA, II or large IB non-small cell lung cancer (NSCLC).
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: Neuwave NEU_2017_06
Protocol Title: A Multicenter Study of the NEUWAVE Fex Microwave Ablation System in the Ablation of Medically Inoperable Primary Soft Tissue Lesions of the Lung: An Initial Experience
Eligibility: Men or women, ages 18 and older, lung cancer nodule not appropriate for surgery or elect not to have surgery
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: GSK FSP 205801
Protocol Title: A Phase II, Randomized, Open-label Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Eligibility: Men or women, ages 18 and older, diagnosed with non-small cell lung cancer, stage IIB or IV, which has progressed following treatment.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: LUNGMAP
Protocol Title: Master Protocol to evaluate biomarker-driven therapies and immunotherapies in previously-treated non-small cell lung cancer (Lung-MAP Screening Study)
Eligibility: Men or women, ages 18 and older, diagnosed with non-small cell lung cancer, DISEASE MUST BE EITHER ADVANCED, stage IIIB or IV or recurrent.
Contact Information: (910) 715-2200
____________________________________________________________________________________________